Drug intelligence / Profile preview

DWP-09031

Development stage: Discontinued
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWP-09031 is a small molecule drug developed by Daewoong Pharmaceutical. It acts as an inhibitor of beta amyloid A4 protein (APP), targeting the aggregation of beta-amyloid peptides implicated in Alzheimer's disease pathology. The compound is designed to bind to beta-amyloid peptide and block its aggregation into toxic oligomers; this may facilitate the transport of soluble beta-amyloid out of the brain via low-density lipoprotein receptor-related protein (LRP) scavenger receptors. Its primary indication was for Alzheimer's disease. Clinical development reached Phase 1 but has since been discontinued[1][2][3].

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on DWP-09031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWP-09031.

Explore the full profile